Dose-related use of NSAIDs together with TNFi in AS patients has a synergistic effect in slowing radiographic progression. The greatest effect is seen in those using both high-dose NSAIDs and TNFi. Of all NSAIDs, celecoxib appears to confer the greatest benefit in decreasing progression with effect at both 2 and 4 years. According to Dr Gensler (University of California San Francisco Medical Center, US), the potential of TNFi and/or NSAIDs to reduce radiographic progression in AS was uncertain.
Until now, causal effects of both exposures on radiographic progression have not been convincingly demonstrated. In addition, no study has evaluated whether effects are comparable among different NSAIDs in this setting. Therefore, Gensler et al. explored the causal effects of TNFi on radiographic progression in AS and determined whether the NSAID dose and type impact this relationship.
A total of 519 adult patients from the Prospective Study of Outcomes in Ankylosing Spondyli...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Switching to Biosimilar bDMARDs Is Safe and Efficacious Next Article
Apremilast Significantly Improves Psoriatic Arthritis in the Long-term »
Table of Contents: EULAR 2018
Psoriasis and Psoriatic Arthritis
Osteoporosis and Osteoarthritis
Systemic Sclerosis and Systemic Lupus Erythematosus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.